{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:14:54Z","timestamp":1784888094857,"version":"3.55.0"},"reference-count":32,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent studies have reported that patients with von Willebrand disease treated perioperatively with a von Willebrand factor (VWF)\/factor VIII (FVIII) concentrate with a ratio of 2.4:1 (Humate P\/Haemate P) often present with VWF and\/or FVIII levels outside of prespecified target levels necessary to prevent bleeding. Pharmacokinetic (PK)-guided dosing may resolve this problem. As clinical guidelines increasingly recommend aiming for certain target levels of both VWF and FVIII, application of an integrated population PK model describing both VWF activity (VWF:Act) and FVIII levels may improve dosing and quality of care. In total, 695 VWF:Act and 894 FVIII level measurements from 118 patients (174 surgeries) who were treated perioperatively with the VWF\/FVIII concentrate were used to develop this population PK model using nonlinear mixed-effects modeling. VWF:Act and FVIII levels were analyzed simultaneously using a turnover model. The protective effect of VWF:Act on FVIII clearance was described with an inhibitory maximum effect function. An average perioperative VWF:Act level of 1.23 IU\/mL decreased FVIII clearance from 460 mL\/h to 264 mL\/h, and increased FVIII half-life from 6.6 to 11.4 hours. Clearly, in the presence of VWF, FVIII clearance decreased with a concomitant increase of FVIII half-life, clarifying the higher FVIII levels observed after repetitive dosing with this concentrate. VWF:Act and FVIII levels during perioperative treatment were described adequately by this newly developed integrated population PK model. Clinical application of this model may facilitate more accurate targeting of VWF:Act and FVIII levels during perioperative treatment with this specific VWF\/FVIII concentrate (Humate P\/Haemate P).<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003891","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T16:36:27Z","timestamp":1615221387000},"page":"1513-1522","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Population pharmacokinetics of the von Willebrand factor\u2013factor VIII interaction in patients with von Willebrand disease"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7967-1023","authenticated-orcid":false,"given":"Laura H.","family":"Bukkems","sequence":"first","affiliation":[{"name":"Hospital Pharmacy\u2013Clinical Pharmacology, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1069-8097","authenticated-orcid":false,"given":"Jessica M.","family":"Heijdra","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Erasmus MC\u2013Sophia Children\u2019s Hospital, University Medical Center Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico C. B.","family":"de Jager","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy\u2013Clinical Pharmacology, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrika C. A. M.","family":"Hazendonk","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Erasmus MC\u2013Sophia Children\u2019s Hospital, University Medical Center Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0904-4360","authenticated-orcid":false,"given":"Karin","family":"Fijnvandraat","sequence":"additional","affiliation":[{"name":"Pediatric Hematology, Emma Children\u2019s Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9447-0465","authenticated-orcid":false,"given":"Karina","family":"Meijer","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen C. J.","family":"Eikenboom","sequence":"additional","affiliation":[{"name":"Division of Thrombosis and Hemostasis, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta A. P.","family":"Laros-van Gorkom","sequence":"additional","affiliation":[{"name":"Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank W. G.","family":"Leebeek","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus MC, University Medical Center Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1557-2995","authenticated-orcid":false,"given":"Marjon H.","family":"Cnossen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Erasmus MC\u2013Sophia Children\u2019s Hospital, University Medical Center Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron A. A.","family":"Math\u00f4t","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy\u2013Clinical Pharmacology, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"issue":"2","key":"2021030816353813100_B1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)","volume":"14","author":"Nichols","year":"2008","journal-title":"Haemophilia"},{"issue":"21","key":"2021030816353813100_B2","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"Von Willebrand\u2019s disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"2021030816353813100_B3","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","article-title":"Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor","volume":"4","author":"Sadler","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2021030816353813100_B4","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1046\/j.1538-7836.2003.00190.x","article-title":"Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP)","volume":"1","author":"Kaufmann","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"14","key":"2021030816353813100_B5","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s40265-017-0793-2","article-title":"Current and emerging options for the management of inherited von Willebrand disease","volume":"77","author":"Heijdra","year":"2017","journal-title":"Drugs"},{"issue":"10","key":"2021030816353813100_B6","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1111\/j.1538-7836.2005.01435.x","article-title":"Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation\/removal methods","volume":"3","author":"Goudemand","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"17","key":"2021030816353813100_B7","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-02-629873","article-title":"Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease [published correction appears in Blood. 2016;127(22):2777]","volume":"126","author":"Gill","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2021030816353813100_B8","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1160\/TH05-01-0013","article-title":"Elevated factor VIII is a risk factor for idiopathic venous thromboembolism in Canada \u2013 is it necessary to define a new upper reference range for factor VIII?","volume":"93","author":"Wells","year":"2005","journal-title":"Thromb Haemost"},{"issue":"7","key":"2021030816353813100_B9","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra040403","article-title":"Treatment of von Willebrand\u2019s disease","volume":"351","author":"Mannucci","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"2021030816353813100_B10","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/hae.13106","article-title":"Efficacy and safety of a VWF\/FVIII concentrate (Wilate\u00ae) in inherited von Willebrand disease patients undergoing surgical procedures","volume":"23","author":"Srivastava","year":"2017","journal-title":"Haemophilia"},{"issue":"5","key":"2021030816353813100_B11","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1365-2516.2011.02603.x","article-title":"Repeated infusions of VWF\/FVIII concentrate: impact of VWF:FVIII ratio on FVIII trough and peak levels in a rabbit model","volume":"17","author":"Raquet","year":"2011","journal-title":"Haemophilia"},{"key":"2021030816353813100_B12","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0049-3848(09)70152-5","article-title":"Haemate P\/Humate-P: a systematic review","volume":"124","author":"Berntorp","year":"2009","journal-title":"Thromb Res"},{"issue":"10","key":"2021030816353813100_B13","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1111\/trf.14241","article-title":"Safety of a pasteurized plasma-derived Factor VIII and von Willebrand factor concentrate: analysis of 33 years of pharmacovigilance data","volume":"57","author":"Kouides","year":"2017","journal-title":"Transfusion"},{"issue":"3","key":"2021030816353813100_B14","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/hae.13451","article-title":"Analysis of current perioperative management with Haemate\u00ae P\/Humate P\u00ae in von Willebrand disease: identifying the need for personalized treatment","volume":"24","author":"Hazendonk","year":"2018","journal-title":"Haemophilia"},{"issue":"6","key":"2021030816353813100_B15","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2516.2011.02534.x","article-title":"von Willebrand factor\/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease","volume":"17","author":"Gill","year":"2011","journal-title":"Haemophilia"},{"key":"2021030816353813100_B16","first-page":"s33","article-title":"Surgical prophylaxis in von Willebrand\u2019s disease: a difficult balance to manage","volume":"6","author":"Franchini","year":"2008","journal-title":"Blood Transfus"},{"issue":"7","key":"2021030816353813100_B17","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1538-7836.2007.02588.x","article-title":"von Willebrand factor\/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery","volume":"5","author":"Lethagen","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2021030816353813100_B18","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1365-2516.2011.02583.x","article-title":"Presurgical pharmacokinetic analysis of a von Willebrand factor\/factor VIII (VWF\/FVIII) concentrate in patients with von Willebrand\u2019s disease (VWD) has limited value in dosing for surgery","volume":"17","author":"Di Paola","year":"2011","journal-title":"Haemophilia"},{"issue":"2","key":"2021030816353813100_B19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/jth.14652","article-title":"One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P\u00ae \/Humate P\u00ae treatment in von Willebrand disease patients","volume":"18","author":"de Jager","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2021030816353813100_B20","volume-title":"Richtlijn: Diagnostiek en Behandeling van Hemofilie en Aanverwante Hemostasestoornissen","author":"Nederlandse Vereniging van Hemofiliebehandelaars (NVHB)","year":"2009"},{"issue":"4","key":"2021030816353813100_B21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.13064","article-title":"The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology","volume":"167","author":"Laffan","year":"2014","journal-title":"Br J Haematol"},{"issue":"12","key":"2021030816353813100_B22","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00228-014-1759-x","article-title":"Adjustment of endogenous concentrations in pharmacokinetic modeling","volume":"70","author":"Bauer","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"2021030816353813100_B23","volume-title":"Pharamcokinetic and Pharmacodynamic Data Analysis: Concepts and Applications","author":"Gabrielsson","year":"2000"},{"key":"2021030816353813100_B24","first-page":"38","article-title":"ASA provides examples to each ASA physical status class","volume":"79","author":"Abouleish","year":"2015","journal-title":"ASA Monitor"},{"issue":"10","key":"2021030816353813100_B25","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood.V86.10.3676.bloodjournal86103676","article-title":"Surgery and anesthesia in sickle cell disease","volume":"86","author":"Koshy","year":"1995","journal-title":"Blood"},{"issue":"4","key":"2021030816353813100_B26","first-page":"494","article-title":"Factor VIII half-life and clinical phenotype of severe hemophilia A","volume":"90","author":"van Dijk","year":"2005","journal-title":"Haematologica"},{"issue":"10","key":"2021030816353813100_B27","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00228-009-0676-x","article-title":"Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A","volume":"65","author":"Bj\u00f6rkman","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"issue":"16","key":"2021030816353813100_B28","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2016-04-713289","article-title":"Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A","volume":"128","author":"Pipe","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2021030816353813100_B29","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2141.1982.tb03888.x","article-title":"Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand\u2019s disease","volume":"52","author":"Tuddenham","year":"1982","journal-title":"Br J Haematol"},{"issue":"4","key":"2021030816353813100_B30","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2141.1994.tb05127.x","article-title":"Biological effect of desmopressin in eight patients with type 2N (\u201cNormandy\u201d) von Willebrand disease","volume":"88","author":"Mazurier","year":"1994","journal-title":"Br J Haematol"},{"issue":"1","key":"2021030816353813100_B31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/bjh.15277","article-title":"Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease","volume":"182","author":"Atiq","year":"2018","journal-title":"Br J Haematol"},{"issue":"2","key":"2021030816353813100_B32","first-page":"279","article-title":"The pharmacokinetic diversity of two von Willebrand factor (VWF)\/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study","volume":"106","author":"Kessler","year":"2011","journal-title":"Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/5\/1513\/1801988\/advancesadv2020003891.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/5\/1513\/1801988\/advancesadv2020003891.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T18:18:36Z","timestamp":1697998716000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/5\/1513\/475406\/Population-pharmacokinetics-of-the-von-Willebrand"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,3,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003891","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,8]]}}}